Hypoglycemia from reduced insulin clearance as GFR declines

Diabetic Nephropathyhard

A 54-year-old man with type 2 diabetes, hypertension, and CKD stage 3b has 3 months of morning palpitations and diaphoresis that improve after breakfast, with glucose readings of 40–50 mg/dL. His insulin regimen and diet have not changed in 2 years. He takes insulin glargine and canagliflozin and has excellent injection technique. One year ago vs today: creatinine 2.5 vs 3.5 mg/dL; fasting glucose 118 vs 123 mg/dL; urine ACR 365 vs 500 mg/g; HbA1c 7.6% vs 6.2%. Electrolytes and BUN are normal and stable. What is the most likely cause of his morning hypoglycemia?

  1. A.Decreased insulin clearanceCorrect
  2. B.Increased urinary glucose excretion
  3. C.Decreased oral intake
  4. D.Increased insulin sensitivity

Explanation

The most likely cause is decreased insulin clearance. Over the past year his creatinine has risen from 2.5 to 3.5 mg/dL, indicating a substantial fall in GFR, while his insulin dose and diet have not changed. The kidney normally removes about one third of circulating insulin, by glomerular filtration with proximal tubular uptake and degradation and by peritubular uptake, and this contribution matters even more for exogenous insulin, which bypasses first-pass hepatic extraction. As GFR declines, particularly below about 20 to 30 mL/min/1.73 m², the half-life of insulin lengthens, so a previously appropriate dose of long-acting glargine now produces excess overnight insulin effect and fasting hypoglycemia. Reduced renal gluconeogenesis, which normally supplies a meaningful share of glucose during fasting, contributes further. The fall in HbA1c from 7.6% to 6.2% reflects this lower average glucose. Basal insulin should be reduced, often by 25% or more, and CKD guidance recommends closer glucose monitoring and dose adjustment as eGFR falls. Decreased oral intake would be an important consideration, but he reports no dietary changes for two years, and the timing tracks his decline in kidney function. Increased urinary glucose excretion from canagliflozin is not the explanation. SGLT2 inhibitors cause little hypoglycemia because their glucosuric effect falls as glucose and GFR decline, and their glucose-lowering effect becomes minimal at an eGFR in this range; the drug has also been unchanged. Increased insulin sensitivity would be unexpected. Advancing CKD is associated with worsening insulin resistance from uremic toxins, metabolic acidosis, inflammation, and vitamin D deficiency, so tissue sensitivity to insulin is more likely to fall than rise.

Why each option

A.
Correct. Creatinine rising from 2.5 to 3.5 mg/dL reduces renal insulin degradation, prolonging glargine action and causing fasting hypoglycemia on an unchanged dose.
B.
Canagliflozin rarely causes hypoglycemia, and its glucosuric effect diminishes as GFR falls, so it cannot explain new morning hypoglycemia on an unchanged dose.
C.
He reports no dietary change in two years, and the onset of hypoglycemia parallels his falling GFR rather than any reduction in food intake.
D.
Advancing CKD worsens insulin resistance through uremic toxins, acidosis, and inflammation, so sensitivity is more likely to decrease than increase here.

Reference: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD; Snyder RW, Semin Dial 2004 (Insulin and oral agents for managing diabetes in dialysis patients)

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Diabetic Nephropathy questions

Browse other topics